HLS — HLS Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$148.27m
- CA$237.94m
- $63.07m
- 54
- 68
- 41
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -19.6 | -15.3 | -13.1 | -23.6 | -27.5 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 13 | 1.64 | 0.123 | 3.92 | 9.53 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.65 | -7.67 | -1.98 | 2.08 | 2.55 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 26.4 | 9.34 | 16.4 | 16.9 | 15.8 |
Capital Expenditures | -2.56 | -32.6 | -0.69 | -0.148 | -0.189 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -12.8 | -12.1 | -3.82 | -10 | 0 |
Acquisition of Business | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -15.4 | -44.7 | -4.51 | -10.1 | -0.189 |
Financing Cash Flow Items | -3.65 | -0.658 | 0 | -0.639 | -1.36 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 23.9 | 9.56 | -11.4 | -6.86 | -14.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 36.1 | -26.5 | 0.567 | -0.456 | 1.23 |